175 related articles for article (PubMed ID: 22752226)
1. Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.
Ziliak D; Gamazon ER; Lacroix B; Kyung Im H; Wen Y; Huang RS
Mol Cancer Ther; 2012 Sep; 11(9):2054-61. PubMed ID: 22752226
[TBL] [Abstract][Full Text] [Related]
2. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity.
LaCroix B; Gamazon ER; Lenkala D; Im HK; Geeleher P; Ziliak D; Cox NJ; Huang RS
BMC Genomics; 2014 Apr; 15():292. PubMed ID: 24739237
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
[TBL] [Abstract][Full Text] [Related]
4. CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29.
Yang Z; Liu C; Wu H; Xie Y; Gao H; Zhang X
BMC Cancer; 2019 Oct; 19(1):948. PubMed ID: 31615563
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity.
Gamazon ER; Im HK; O'Donnell PH; Ziliak D; Stark AL; Cox NJ; Dolan ME; Huang RS
Mol Cancer Ther; 2011 Mar; 10(3):472-80. PubMed ID: 21252287
[TBL] [Abstract][Full Text] [Related]
6. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
7. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
8. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
Song L; Li Y; Li W; Wu S; Li Z
J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
[TBL] [Abstract][Full Text] [Related]
9. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants.
O'Donnell PH; Gamazon E; Zhang W; Stark AL; Kistner-Griffin EO; Stephanie Huang R; Eileen Dolan M
Pharmacogenet Genomics; 2010 May; 20(5):327-37. PubMed ID: 20393316
[TBL] [Abstract][Full Text] [Related]
10. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
11. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
[TBL] [Abstract][Full Text] [Related]
12. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
13. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
15. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
17. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
18. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
Yin W; Nie Y; Zhang Z; Xie L; He X
Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
20. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.
Huang RS; Johnatty SE; Gamazon ER; Im HK; Ziliak D; Duan S; Zhang W; Kistner EO; Chen P; Beesley J; Mi S; O'Donnell PH; Fraiman YS; Das S; Cox NJ; Lu Y; Macgregor S; Goode EL; Vierkant RA; Fridley BL; Hogdall E; Kjaer SK; Jensen A; Moysich KB; Grasela M; Odunsi K; Brown R; Paul J; Lambrechts D; Despierre E; Vergote I; Gross J; Karlan BY; Defazio A; Chenevix-Trench G; ; Dolan ME
Clin Cancer Res; 2011 Aug; 17(16):5490-500. PubMed ID: 21705454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
